missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human TPR (aa 517-656) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (91%), Rat (91%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-54049 (PA5-54049. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Steroidogenic factor-1 (SF-1) regulates multiple genes involved in the adrenal and gonadal development and in the biosynthesis of a variety of hormones, including adrenal and gonadal steroids, anti-Mullerian hormone (AMH), and gonadotropins. SF-1 belongs to the fushi tarazu factor-1 (FTZ-F1) subfamily of orphan nuclear receptors. In the adult ovary, SF-1 localizes to theca/interstitial cells.
Specifications
Specifications
| Accession Number | P12270 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 7175 |
| Name | Human TPR (aa 517-656) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2610029M07Rik; C77892; Megator; NPC-associated intranuclear protein; nuclear pore complex-associated protein Tpr; nucleoprotein TPR; nucleoprotein TPR-like protein; Tpr; translocated promoter region (to activated MET oncogene); translocated promoter region and nuclear basket protein; Translocated promoter region protein; translocated promoter region, nuclear basket protein; tumor potentiating region |
| Common Name | TPR |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction